A Phase 1 interventional study of Pomalidomide 4 MG Oral Capsule and Pomalidomide 4 MG Oral Capsule-Pomalyst in Bioequivalence, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-07.
Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.
Exclusion Criteria:
per os,capsule,4mg,1 capsule per period
Drug: Pomalidomide 4 MG Oral Capsule
per os,capsule,4mg,1 capsule per period
Drug: Pomalidomide 4 MG Oral Capsule-Pomalyst
per os,capsule,4mg,1 capsule per period
per os,capsule,4mg,1 capsule per period
Peak Plasma Concentration (Cmax)
90% CI of T/R within 80-125%
Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.
Area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC0-t)
90% CI of T/R within 80-125%
Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.
Area under the plasma concentration versus time curve from 0 to infinity (AUC0-inf)
90% CI of T/R within 80-125%
Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Simcere Pharmaceutical Co., Ltd.